ARCHIVES

Motesanib Does Not Improve OS; Study Doesn’t Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

NCI budget: a “Yes” to one thing means a “No” to something else, director says.

February 27, 2004

NDA n Vp-16 Goes to Advisory Committee Sept. 30

August 27, 1982

Committee Recommends FDA Approval Of Three New Drugs For Cancer Treatment

March 27, 1998

NCI Considering Adoption Of NIGMS Guidelines To Limit Growth Of Renewals, Ensure New Grants

November 30, 1990

More money would speed progress, NCI says, but backs off previous commitment to meet 2015 goal by 2010.

July 29, 2005

Breast Cancer Rates Decline Most for Affluent White Women

February 26, 2010